Navigation Links
MDS Nordion Divests Non Strategic Product Lines
Date:11/29/2007

Signs contract with Best Medical International Inc.

OTTAWA, Nov. 29 /PRNewswire-FirstCall/ - MDS Nordion, a leading provider of medical isotopes and radiopharmaceuticals, today signed an agreement with Best Medical International Inc. to divest its external beam therapy and self-contained irradiator product lines. The sale is a key part of MDS Nordion's growth strategy to focus its resources on being a leading innovator in molecular medicine.

Under the terms of this agreement, Best Medical International Inc., a provider of radiotherapy and oncology products, will purchase MDS Nordion's external beam therapy and self-contained irradiator product lines. External beam therapy equipment is used in the treatment of cancer, and self-contained irradiators are used for the irradiation of blood to prevent disease and for research purposes. Best Medical International Inc. will acquire these two product lines with combined annualized revenues of US $32 million and approximately 150 employees. The transaction is expected to close over the next three months. The financial terms are not being disclosed.

"This sale represents a further focusing of our business at MDS Nordion," said Steve West, President, MDS Nordion. "By divesting these product lines, we can direct all of our energy and resources on becoming a leading innovator in the exciting and growing field of molecular medicine."

The external beam therapy units and blood irradiators are complementary to the kinds of medical equipment manufactured by Best Medical International Inc. With a strategic focus on improving medical care in developing countries, Best Medical International Inc. will provide an opportunity to expand these product lines.

"These product lines are a great fit with our company," said Krishnan Suthanthiran, President, Best Medical International Inc. "The external beam cancer therapy product line complements our portfolio as we will now be able to offer the equipment and services required to set up cancer treatment centres, a move towards our goal of launching war on cancer globally."

About MDS Nordion

MDS Nordion (http://www.mdsnordion.com) is a world leader in medical isotopes, radiation and related technologies. It is a business unit of MDS Inc. (TSX:MDS)(NYSE:MDZ). MDS Inc. is a global life sciences company that provides market-leading products and services for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS Inc. has more than 6,200 highly skilled people in 28 countries. Find out more at http://www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.

About Best Medical International Inc.

For 30 years, Best Medical has served the medical community with the highest quality products and unparalleled customer service. Our brachytherapy seeds, gold fiducial markers, supplies, accessories and exam equipment exemplify our commitment to uncompromised quality and safety. Best Medical International now encompasses a family of trusted companies and organizations with a proven track record of innovation, quality and service in external beam radiation therapy, brachytherapy and vascular brachytherapy solutions. Find out more at http://www.teambest.com.


'/>"/>
SOURCE MDS Nordion
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. MDS Nordion signs 17-year contract with Rosenergoatom
2. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
3. Martopia(R) Forms Strategic Alliance With Modern Healthcare Magazine
4. LehmanMillet Continues Expansion with Strategic Hires
5. Stille and Enova Form Strategic Partnership to Introduce Worlds Brightest LED Cordless Surgical Headlights Into Europe and Japan
6. Benjamin England, Former FDA Regulatory Counsel, to Testify on FDA Import Strategic Plan Before House Appropriations Subcommittee
7. Diet.com Enters Strategic Collaboration To Support Microsoft HealthVault
8. Lumenis Ltd. Announces Senior Leadership Appointments Strengthening the Companys Strategic Businesses
9. Avantium and BP Extend Strategic Partnership
10. 40 86 Strategic Income Fund Declares Dividend
11. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
Breaking Medicine Technology: